Outlook Therapeutics (NASDAQ:OTLK) Announces Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Posted by Joseph Griffin on Dec 29th, 2024

Outlook Therapeutics (NASDAQ:OTLK – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06, Zacks reports.

Outlook Therapeutics Stock Up 18.2 %

Outlook Therapeutics stock opened at $2.01 on Friday. The company has a market capitalization of $47.55 million, a P/E ratio of -0.19 and a beta of 0.46. The firm has a 50 day moving average price of $3.81 and a 200-day moving average price of $5.89. Outlook Therapeutics has a twelve month low of $0.87 and a twelve month high of $12.85.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Chardan Capital reissued a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. Ascendiant Capital Markets dropped their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, September 3rd. BTIG Research reduced their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, November 29th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Outlook Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.73.

Get Our Latest Research Report on Outlook Therapeutics

About Outlook Therapeutics

(Get Free Report)

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.